MedIntelliBase® NewsTips  
November 2005

Your monthly newsletter from the
"better way to access market intelligence" people at

MedIntelliBase NewsTips... A Better stay up-to-date

If you are tired of canned market research reports that are outdated before they are published or databases that do not offer the intelligent insights and analysis you need to make critical decisions about your medical technology development and investments...MedIntelliBase™ is for you.

Each month our MedIntelliBase NewsTips e-newsletter will provide you with glimpses into our MedIntelliBase MarketTracks capturing market, clinical research, company and technology intelligence. Our first four MarketTracks in the Interventional Medicine Series report in-depth on Cardiovascular, Endovascular, Carotid & Stroke, and Neurovascular Therapeutics. Below are a few glimpses into our first and second in that series, our Cardiovascular Market Track and our Endovascular MarketTrack.

Take a moment to learn about this new way to access up-to-date information and intelligence. To provide you with vital information, selected facts and figures, links to our website are noted below. And each month we will send you a new issue of this MedIntelliBase NewsTips to help keep you informed.

Our MedIntelliBase Team - Tyler Mittleider, Jordan Zornes and I - are excited to share this information with you. Use it in good health!

Best regards -

Vicky Hunsicker Sanko
The Next Phase® Publishing, Inc.

Phone - 1-425-869-8724 

MedIntelliBase NewsTips >>

1) Did you know that there are at least 232 stents worldwide developed for cardiovascular intervention alone that are either commercial, in-development, or tried and failed?  We provide the vital statistics for all of them in our MIB SMArt Chart™ of Competing Technologies Database. The breakdown by stent type is:

  • 117 Bare Metal Stents (BMS)
  • 6 Bioabsorbable Stents
  • 69 Coated Stents
  • 40 Drug-Eluting Stents (DES)

See our website for more information and a FREE copy of the SMArt Chart Database Index listing all of these stents at

2) Our MIB Clinical Trials Database captures 432 pivotal clinical trials and registries, the majority published since 2000. Of the total, 279 are Cardiovascular and 153 are Peripheral Vascular, including clinical trial descriptions, PIs and PI sites, trial designs, results and conclusions. Of the 153 Peripheral Vascular, 54 are Neurovascular and 99 are Peripheral Vascular (below the aortic arch). And we continue to add more as breaking trial results are released from the TCT2005, AHA, Dr. Frank J. Veith and other conferences throughout this fall and winter. Stay tuned!

3) You may be interested to know about new products announced, clinical trials and registries results reported over this last year and other market events. A few are offered below:

The cardiovascular stent market has moved forward with numerous approvals granted over the last several months. Recently CE Marks have been awarded to:

  • Axxion paclitaxel-eluting stent from Occam International
  • Endeavor ABT-578-eluting stent from Medtronic
  • And more...

FDA Approval has been granted for the:

  • Liberté bare metal stent by Boston Scientific, which also has been launched in at least 18 countries in Asia, Africa, and South America
  • Rithron-XR coronary stent system from Biotronik
  • And more... 

Japanese approval has been obtained by the:

  • Cypher stent as of April 2005 
  • Updates to the MedIntelliBase Database, "Clinical Trial Database," specifically related to the following stents:
  • Liberté bare metal stent by Boston Scientific, which also has been launched in at least 18 countries in Asia, Africa, and South America
  • CoStar paclitaxel-eluting stent by Biotronik in COSTAR II and EUROSTAR
  • Endeavor stent in the ENDEAVOR series of trials
  • And more...

Several new drug-eluting cardiovascular stents have been added to our SMArt Chart Database of Competing Technologies including the:

  • Supralimus sirolimus-eluting coronary stent by MIV Therapeutics
  • Barracuda paclitaxel-eluting stent by Boston Scientific
  • And more...

Moving beyond medical devices and into drugs, many new therapies being evaluated for the CV market have been added to the SMArt Chart Database of Competing Technologies:

  • Imatinib Mesylate (Gleevec), a PDGF inhibitor by Novartis, is being evaluated to understand its role in reducing cell proliferation and restenosis
  • Midostarin from Novartis is a FGF protein kinase and extracellular matrix inhibitor scheduled to be tested in combination with Conor Medsystems' cobalt chromium stent platform in the treatment of restenosis
  • And more...

Other early development stage pharmaceutical compounds have been added to the SMArt Chart Database of Competing Technologies:

  • MLN1202 by Millennium Pharmaceuticals is a novel humanized monoclonal antibody currently in a Phase II clinical trial evaluating its anti-inflammatory effects
  • VT-111 by Viron Therapeutics is a virally-derived anti-inflammatory protein that has cleared Phase I studies and is currently in a Phase II study evaluating its effects on restenosis rates and circulating biochemical inflammatory markers
  • And more...

Updates have been added to the gene therapy and other advanced therapies modalities sections of the SMArt Chart Database of Competing Technologies as well:

  • 6R-BH4 (tetrahydrobiopterin) by BioMarin Pharmaceutical is being developed pre-clinically in collaboration with Soreno as a NO synthesis enhancer and is being studied to evaluate its ability to improve vascular endothelial function
  • Corautus Genetics is evaluating a naked DNA plasmid form of VEGF-2 in the Phase IIb GENASIS trial to assess its ability to promote therapeutic angiogenesis
  • And more...

Finally, several general market events have been captured in this update within the SMArt Chart Database of Competing Technologies:

  • CV brachytherapy systems will no longer be available following Novoste's exit from the market.  Novoste entered into a definitive agreement to merge with ONI Medical Systems in May 2005.  The company will operate as ONI Medical Systems and focus on MRI systems for orthopedic surgeons.
  • Orbus Medical Technologies was acquired by Neich Medical in January 2005 and became OrbusNeich.   Neich Medical was previously the distributor of Orbus products in Asia Pacific and produced the delivery systems for Orbus' stents.
  • And more...

Contact us >> if you need more information. We will be pleased to help you access the critical intelligence you need to make informed product development and business investment decisions.

FYI: MedIntelliBase's new website further explains the other innovative market intelligence and guidance documents we offer you. To learn more visit the MedIntelliBase home page .

If you have a medical technology-related question, call or email me, Vicky Hunsicker Sanko. If I don't know the answer, I'll find out.

You can find other related services at our sister division's website at The Next Phase Consultancy's Home Page.


1) MedIntelliBase NewsTips is free and you are welcome to continue receiving it as long as you wish. If at any time you wish to cancel, just reply and type "Remove MIB NewsTips" in the text block and provide us with the email address we used to send this MIB NewsTips to you so we are sure to properly remove you form our list. You'll receive no more issues.

2) We will not share your name, e-mail address or contact information with anyone.

3) Feel free to share or reproduce the information in this MedIntelliBase NewsTips e-newsletter (in whole or part) as long as proper mention and copyright notice is given to MedIntelliBase and The Next Phase Publishing, Inc.

4) If you are not the original recipient of this newsletter and would like to receive future issues, just drop me a line.

© The Next Phase Publishing, Inc. 2005. All rights reserved.


Editor: Vicky Hunsicker Sanko
The Next Phase Publishing, Inc.
Phone - 1-425-869-8724
Fax - 1-425-869-9397

We also publish a free monthly e-newsletter on device discovery, definition and development as well as related customer needs analysis, market research, and business development issues called NextTip™ Insight. See past issues at